The Clinical Utility of Autoantibodies in Patients with Idiopathic Granulomatous Mastitis
Background Although the etiopathogenesis of idiopathic granulomatous mastitis (IGM) is still controversial, recently autoimmunity and immune dysregulation have been emphasized. The aim of this study is to investigate the clinical utility of autoantibodies in IGM. Material and Methods Rheumatoid fact...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-02-01
|
| Series: | Journal of Investigative Surgery |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/08941939.2020.1861666 |
| _version_ | 1797684500019281920 |
|---|---|
| author | Hande Koksal |
| author_facet | Hande Koksal |
| author_sort | Hande Koksal |
| collection | DOAJ |
| description | Background Although the etiopathogenesis of idiopathic granulomatous mastitis (IGM) is still controversial, recently autoimmunity and immune dysregulation have been emphasized. The aim of this study is to investigate the clinical utility of autoantibodies in IGM. Material and Methods Rheumatoid factor (RF), antinuclear antibody (ANA), anti-double stranded DNA antibody (anti-ds-DNA), anti-cyclic citrullinated peptides antibody (anti-CCP) and perinuclear anti-neutrophil cytoplasmic antibody (pANCA) levels were investigated in pathologically diagnosed IGM patients (Group IGM) and healthy women (Group C). IGM patients were divided into two groups as those with active symptoms and signs (Group IGMA) and those without clinical and radiological findings (Group IGMR). Results While, in Group IGM, the positivity of RF, ANA, anti-ds-DNA, pANCA and anti-CCP was 13.1%, 3.3%, 1.6%, 0%, and 3.3%, respectively, in Group C, they were 13.3%, 0%, 0%, 0%, and 0%, respectively. The differences were not statistically significant (p > .05). In Groups IGMA, IGMR and C, RF positivity was 10%, 16.1%, and 13.3%, respectively. The ANA positivity of Groups IGMA, IGMR and C was 0%, 6.5%, and 0%, respectively. Groups IGMA, IGMR and C’s anti-ds-DNA positivity were 0%, 3.2%, and 0%, respectively. In all groups, pANCA was negative. The anti-CCP positivity of Groups IGMA, IGMR and C was 6.7%, 0%, and 0%, respectively. Conclusion Our findings did not support the clinical utility of autoantibodies including RF, ANA, anti-ds-DNA, pANCA and anti-CCP in IGM. |
| first_indexed | 2024-03-12T00:31:37Z |
| format | Article |
| id | doaj.art-cb9213aa66e3404f939570e39ebf3390 |
| institution | Directory Open Access Journal |
| issn | 0894-1939 1521-0553 |
| language | English |
| last_indexed | 2024-03-12T00:31:37Z |
| publishDate | 2022-02-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Investigative Surgery |
| spelling | doaj.art-cb9213aa66e3404f939570e39ebf33902023-09-15T10:21:27ZengTaylor & Francis GroupJournal of Investigative Surgery0894-19391521-05532022-02-0135232532910.1080/08941939.2020.18616661861666The Clinical Utility of Autoantibodies in Patients with Idiopathic Granulomatous MastitisHande Koksal0Department of General Surgery, Saglik Bilimleri University, Hamidiye Faculty of Medicine, Ministry of Health Konya City HospitalBackground Although the etiopathogenesis of idiopathic granulomatous mastitis (IGM) is still controversial, recently autoimmunity and immune dysregulation have been emphasized. The aim of this study is to investigate the clinical utility of autoantibodies in IGM. Material and Methods Rheumatoid factor (RF), antinuclear antibody (ANA), anti-double stranded DNA antibody (anti-ds-DNA), anti-cyclic citrullinated peptides antibody (anti-CCP) and perinuclear anti-neutrophil cytoplasmic antibody (pANCA) levels were investigated in pathologically diagnosed IGM patients (Group IGM) and healthy women (Group C). IGM patients were divided into two groups as those with active symptoms and signs (Group IGMA) and those without clinical and radiological findings (Group IGMR). Results While, in Group IGM, the positivity of RF, ANA, anti-ds-DNA, pANCA and anti-CCP was 13.1%, 3.3%, 1.6%, 0%, and 3.3%, respectively, in Group C, they were 13.3%, 0%, 0%, 0%, and 0%, respectively. The differences were not statistically significant (p > .05). In Groups IGMA, IGMR and C, RF positivity was 10%, 16.1%, and 13.3%, respectively. The ANA positivity of Groups IGMA, IGMR and C was 0%, 6.5%, and 0%, respectively. Groups IGMA, IGMR and C’s anti-ds-DNA positivity were 0%, 3.2%, and 0%, respectively. In all groups, pANCA was negative. The anti-CCP positivity of Groups IGMA, IGMR and C was 6.7%, 0%, and 0%, respectively. Conclusion Our findings did not support the clinical utility of autoantibodies including RF, ANA, anti-ds-DNA, pANCA and anti-CCP in IGM.http://dx.doi.org/10.1080/08941939.2020.1861666rheumatoid factorantinuclear antibody anti-double stranded dna antibodyanti-cyclic citrullinated peptides antibodyperinuclear anti-neutrophil cytoplasmic antibodyidiopathic granulomatous mastitis |
| spellingShingle | Hande Koksal The Clinical Utility of Autoantibodies in Patients with Idiopathic Granulomatous Mastitis Journal of Investigative Surgery rheumatoid factor antinuclear antibody anti-double stranded dna antibody anti-cyclic citrullinated peptides antibody perinuclear anti-neutrophil cytoplasmic antibody idiopathic granulomatous mastitis |
| title | The Clinical Utility of Autoantibodies in Patients with Idiopathic Granulomatous Mastitis |
| title_full | The Clinical Utility of Autoantibodies in Patients with Idiopathic Granulomatous Mastitis |
| title_fullStr | The Clinical Utility of Autoantibodies in Patients with Idiopathic Granulomatous Mastitis |
| title_full_unstemmed | The Clinical Utility of Autoantibodies in Patients with Idiopathic Granulomatous Mastitis |
| title_short | The Clinical Utility of Autoantibodies in Patients with Idiopathic Granulomatous Mastitis |
| title_sort | clinical utility of autoantibodies in patients with idiopathic granulomatous mastitis |
| topic | rheumatoid factor antinuclear antibody anti-double stranded dna antibody anti-cyclic citrullinated peptides antibody perinuclear anti-neutrophil cytoplasmic antibody idiopathic granulomatous mastitis |
| url | http://dx.doi.org/10.1080/08941939.2020.1861666 |
| work_keys_str_mv | AT handekoksal theclinicalutilityofautoantibodiesinpatientswithidiopathicgranulomatousmastitis AT handekoksal clinicalutilityofautoantibodiesinpatientswithidiopathicgranulomatousmastitis |